首页> 外文学位 >Patterns of Use and Safety of Human Papillomavirus Vaccines among Adolescents in the United States
【24h】

Patterns of Use and Safety of Human Papillomavirus Vaccines among Adolescents in the United States

机译:在美国青少年中使用人乳头瘤病毒疫苗的模式和安全性

获取原文
获取原文并翻译 | 示例

摘要

Phase III clinical trials and post-licensure surveillance have demonstrated the safety and efficacy of human papillomavirus (HPV) vaccines. The U.S. Advisory Committee on Immunization Practices recommends universal HPV vaccination at age 11--12, alongside tetanus-diphtheria-acellular pertussis (Tdap) and meningococcal conjugate (MenACWY) vaccination.;Despite this recommendation, adolescents initiate HPV vaccination less frequently than Tdap and MenACWY vaccination, due partially to concerns about HPV vaccine safety. Reports of complex regional pain syndrome (CRPS) following HPV vaccination in Japan may have exacerbated safety concerns regarding HPV vaccination. To date, however, no epidemiological research has linked HPV vaccination to CRPS. We analyzed private U.S. insurance claims between 2006--2014 to assess 1) patterns of use of HPV vaccination compared to Tdap and MenACWY among adolescents; and 2) the hazard of CRPS following HPV vaccination compared to Tdap and MenACWY among girls.;Among 1,691,223 adolescents, HPV vaccination occurred later than Tdap or MenACWY vaccination. Half of vaccinated adolescents received Tdap and MenACWY vaccination only; however, co-administration of all three vaccines increased with birth cohort. Rural adolescents were less likely than urban adolescents to receive each vaccination except in the Northeast, where they were more likely to receive HPV vaccination (incidence rate ratio: 1.09, 95% CI: 1.05, 1.13). Timely HPV vaccination was associated with female sex, urbanicity, Western residence, and later birth cohort.;We identified 563 CRPS cases among 1,232,572 girls. CRPS hazard was not significantly elevated following recent HPV, Tdap, or MenACWY vaccination. Ever receiving Tdap and MenACWY vaccination were associated with CRPS in crude analysis, but were not associated after adjusting for trauma. Concomitant administration of HPV vaccine with other adolescent vaccines conferred no excess hazard of CRPS. Girls with lower limb injuries had the greatest CRPS hazard compared to girls without (HR: 12.4, 95% CI: 10.4, 14.7), and common pediatric illnesses (e.g. asthma, respiratory infections, allergies) were positively associated with CRPS.;HPV vaccination remains suboptimal among U.S. adolescents. We observed no vaccine safety signals with respect to CRPS, supporting current adolescent vaccination recommendations. Health care providers should strongly recommend timely HPV vaccination with other recommended adolescent vaccines to provide optimal protection against HPV-associated cancers.
机译:III期临床试验和许可后监测证明了人乳头瘤病毒(HPV)疫苗的安全性和有效性。美国免疫实践咨询委员会建议在11--12岁时进行普遍的HPV疫苗接种,同时接种破伤风-白喉无细胞百日咳(Tdap)和脑膜炎球菌结合物(MenACWY)疫苗;尽管如此,青少年开始HPV疫苗接种的频率低于Tdap和进行MenACWY疫苗接种,部分原因是对HPV疫苗安全性的担忧。在日本进行HPV疫苗接种后,关于复杂的局部疼痛综合征(CRPS)的报道可能加剧了有关HPV疫苗接种的安全性问题。然而,迄今为止,尚无流行病学研究将HPV疫苗接种与CRPS联系起来。我们分析了2006--2014年间美国的私人保险理赔,以评估1)青少年中HPV疫苗接种与Tdap和MenACWY相比的使用方式; 2)与Tdap和MenACWY相比,HPV疫苗接种后CRPS的危险性在女孩中。在1,691,223名青少年中,HPV疫苗的接种晚于Tdap或MenACWY疫苗。一半的接种疫苗的青少年仅接受了Tdap和MenACWY疫苗接种;但是,三种疫苗的共同给药随出生队列的增加而增加。农村地区的青少年每次接种疫苗的可能性都低于城市地区的青少年,而东北地区则更容易接受HPV疫苗接种(发生率:1.09,95%CI:1.05,1.13)。及时的HPV疫苗接种与女性,城市化程度,西方居住地和后来的出生队列有关;我们在1,232,572名女孩中鉴定了563例CRPS病例。在最近的HPV,Tdap或MenACWY疫苗接种后,CRPS危害并未显着升高。在粗略分析中,曾经接受过Tdap和MenACWY疫苗接种的患者均与CRPS相关,但在调整创伤后并未相关。 HPV疫苗与其他青春期疫苗的并用不会给CRPS带来过多危害。与没有下肢的女孩相比(HR:12.4,95%CI:10.4,14.7),下肢受伤的女孩具有最大的CRPS危险,并且常见的儿科疾病(例如哮喘,呼吸道感染,过敏)与CRPS呈正相关。在美国青少年中仍然不理想。我们没有观察到关于CRPS的疫苗安全性信号,支持当前的青少年疫苗接种建议。卫生保健提供者应强烈建议及时将HPV疫苗与其他推荐的青春期疫苗一起接种,以提供针对HPV相关癌症的最佳保护。

著录项

  • 作者

    Vielot, Nadja Alexandra.;

  • 作者单位

    The University of North Carolina at Chapel Hill.;

  • 授予单位 The University of North Carolina at Chapel Hill.;
  • 学科 Epidemiology.;Health sciences.;Public health.;Virology.
  • 学位 Ph.D.
  • 年度 2017
  • 页码 89 p.
  • 总页数 89
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号